Author: admin

Yum Brands on Tuesday reported quarterly earnings and revenue growth, fueled by strong demand for Taco Bell and improved U.S. sales for KFC.

The restaurant company also announced plans to review strategic options for Pizza Hut. The embattled pizza chain has struggled to win over diners in recent years. In its home market, pizza fatigue after pandemic lockdowns have led to slumping sales, and rivals like Domino’s Pizza have stolen share from Pizza Hut.

Yum shares rose 2% in premarket trading.

Here’s what Yum reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

• Earnings per share: $1.58 adjusted. May not compare to $1.49 expected.
• Revenue: $1.98 billion vs. $1.97 billion expected

Yum reported third-quarter net income of $397 million, or $1.41 per share, up from $382 million, or $1.35 per share, a year earlier.

Excluding the cost of its strategic review of Pizza Hut and other items, the company earned $1.58 per share.

Net sales rose 8% to $1.98 billion.

Yum’s digital sales, which includes mobile, delivery and kiosk orders, reached $10 billion system-wide and accounted for roughly 60% of orders.

The company’s same-store sales increased 3%, lifted by Taco Bell and KFC.

Taco Bell’s same-store sales climbed 7% in the quarter, topping analyst estimates of 5.2% growth, according to StreetAccount. While other fast-food chains have seen their sales slump, the Mexican-inspired chain has bucked the trend. Its value perception, even among pinched low-income diners, and buzzy menu innovation have helped Taco Bell grow sales.

Yum announced that it is buying 128 Taco Bell locations in the Southeast U.S. The company franchises about 98% of its restaurants.

KFC reported same-store sales growth of 3%, beating StreetAccount estimates of 2.4%. In China, the brand’s largest market, system sales rose 6%. And in the U.S., where it has lost market share to new players like Raising Cane’s, KFC’s same-store sales increased 2%.

Only Pizza Hut saw same-store sales declines. The struggling pizza chain reported same-store sales fell 1% in the quarter, fueled by a 7% drop in sales at U.S. restaurants open at least a year. Analysts surveyed by StreetAccount were projecting same-store sales declines of just 0.3%.

Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period.

The pharmaceutical giant now expects its full-year adjusted profit to come in between $3 and $3.15 per share, up from a previous guidance of $2.90 to $3.10 per share. Pfizer said that reflects its “solid” performance for the year, “continued confidence in our business” and progress with reducing costs, among other factors. 

Pfizer said it also includes a one-time $1.35 billion charge tied to its licensing agreement with Chinese biotech 3SBio, which hit earnings by roughly 20 cents per share. The company said its 2025 guidance also accounts for President Donald Trump’s current tariffs on China, Canada and Mexico, but not his threatened pharmaceutical-specific tariffs.

Pfizer maintained it full-year revenue guidance of $61 billion to $64 billion.

Here’s what the company reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

• Earnings per share: 87 cents adjusted vs. 63 cents expected
• Revenue: $16.65 billion vs. $16.58 billion expected

The results come weeks after Pfizer became the first drugmaker to strike a deal with Trump to voluntarily sell its medications for less, as his administration pushes to link U.S. drug prices to cheaper ones abroad.

Under the deal, Pfizer has agreed to a three-year grace period during which the company’s products won’t face Trump’s threatened pharmaceutical-specific tariffs – as long as the drugmaker further invests in U.S. manufacturing. The company plans to invest $70 billion to reshore domestic drug manufacturing and research facilities.

The results also come as Pfizer escalates a bidding war with Novo Nordisk for the obesity biotech Metsera. Pfizer on Monday filed its second lawsuit against the two companies, alleging that Novo Nordisk’s attempt to outbid Pfizer to acquire Metsera is anticompetitive.